🚀 VC round data is live in beta, check it out!
Yili Chuannig Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Yili Chuannig Biotech and similar public comparables like Dyne Therapeutics, Hubei Jumpcan, Oruka Therapeutics, Emcure Pharmaceuticals and more.
Yili Chuannig Biotech Overview
About Yili Chuannig Biotech
Yili Chuannig Biotechnology Co Ltd adopts the most advanced and mature international biological fermentation, chemical extraction, enzymatic hydrolysis, control and energy saving, and environmental protection technology. The main products of the company include erythromycin thiocyanate, cephalosporin intermediates, penicillin intermediates, and crude ursodeoxycholic acid.
Founded
2010
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$3B
Yili Chuannig Biotech Financials
Yili Chuannig Biotech reported last 12-month revenue of $684M and EBITDA of $233M.
In the same LTM period, Yili Chuannig Biotech generated $198M in gross profit, $233M in EBITDA, and $118M in net income.
Revenue (LTM)
Yili Chuannig Biotech P&L
In the most recent fiscal year, Yili Chuannig Biotech reported revenue of $677M and EBITDA of $229M.
Yili Chuannig Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $684M | XXX | $677M | XXX | XXX | XXX |
| Gross Profit | $198M | XXX | $198M | XXX | XXX | XXX |
| Gross Margin | 29% | XXX | 29% | XXX | XXX | XXX |
| EBITDA | $233M | XXX | $229M | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 34% | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $118M | XXX | $113M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 17% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Yili Chuannig Biotech Stock Performance
Yili Chuannig Biotech has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
Yili Chuannig Biotech's stock price is $1.51.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | 0.0% | XXX | XXX | XXX | $0.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialYili Chuannig Biotech Valuation Multiples
Yili Chuannig Biotech trades at 5.0x EV/Revenue multiple, and 14.8x EV/EBITDA.
EV / Revenue (LTM)
Yili Chuannig Biotech Financial Valuation Multiples
As of April 19, 2026, Yili Chuannig Biotech has market cap of $3B and EV of $3B.
Equity research analysts estimate Yili Chuannig Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Yili Chuannig Biotech has a P/E ratio of 28.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 5.0x | XXX | 5.1x | XXX | XXX | XXX |
| EV/EBITDA | 14.8x | XXX | 15.0x | XXX | XXX | XXX |
| EV/EBIT | 22.7x | XXX | 23.0x | XXX | XXX | XXX |
| EV/Gross Profit | 17.4x | XXX | 17.4x | XXX | XXX | XXX |
| P/E | 28.5x | XXX | 29.9x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 51.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Yili Chuannig Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Yili Chuannig Biotech Margins & Growth Rates
Yili Chuannig Biotech's revenue in the last 12 month grew by 8%.
Yili Chuannig Biotech's rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Yili Chuannig Biotech's rule of X is 51% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Yili Chuannig Biotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | 10% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 41% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 51% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 1% | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | 3% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2% | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 7% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Yili Chuannig Biotech Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Yili Chuannig Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Dyne Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Hubei Jumpcan | XXX | XXX | XXX | XXX | XXX | XXX |
| Oruka Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Emcure Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Jiangsu Nhwa | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Yili Chuannig Biotech M&A Activity
Yili Chuannig Biotech acquired XXX companies to date.
Last acquisition by Yili Chuannig Biotech was on XXXXXXXX, XXXXX. Yili Chuannig Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Yili Chuannig Biotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialYili Chuannig Biotech Investment Activity
Yili Chuannig Biotech invested in XXX companies to date.
Yili Chuannig Biotech made its latest investment on XXXXXXXX, XXXXX. Yili Chuannig Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Yili Chuannig Biotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Yili Chuannig Biotech
| When was Yili Chuannig Biotech founded? | Yili Chuannig Biotech was founded in 2010. |
| Where is Yili Chuannig Biotech headquartered? | Yili Chuannig Biotech is headquartered in China. |
| Is Yili Chuannig Biotech publicly listed? | Yes, Yili Chuannig Biotech is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Yili Chuannig Biotech? | Yili Chuannig Biotech trades under 301301 ticker. |
| When did Yili Chuannig Biotech go public? | Yili Chuannig Biotech went public in 2022. |
| Who are competitors of Yili Chuannig Biotech? | Yili Chuannig Biotech main competitors are Dyne Therapeutics, Hubei Jumpcan, Oruka Therapeutics, Emcure Pharmaceuticals. |
| What is the current market cap of Yili Chuannig Biotech? | Yili Chuannig Biotech's current market cap is $3B. |
| What is the current revenue of Yili Chuannig Biotech? | Yili Chuannig Biotech's last 12 months revenue is $684M. |
| What is the current revenue growth of Yili Chuannig Biotech? | Yili Chuannig Biotech revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Yili Chuannig Biotech? | Current revenue multiple of Yili Chuannig Biotech is 5.0x. |
| Is Yili Chuannig Biotech profitable? | Yes, Yili Chuannig Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Yili Chuannig Biotech? | Yili Chuannig Biotech's last 12 months EBITDA is $233M. |
| What is Yili Chuannig Biotech's EBITDA margin? | Yili Chuannig Biotech's last 12 months EBITDA margin is 34%. |
| What is the current EV/EBITDA multiple of Yili Chuannig Biotech? | Current EBITDA multiple of Yili Chuannig Biotech is 14.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.